Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients

American Journal of Hypertension

Volumn 10, Issue 1, 1997, Pages 1-8

  Alderman, Michael H ^a   Ooi, Wee Lock ^b   Cohen, Hillel ^a   Madhavan, Shantha ^a   Sealey, Jean E ^c   Laragh, John H ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b RESEARCH AND TRAINING INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

blood pressure; hypertension; myocadial infarction; plasma renin activity; sodium

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PREDICTION; PRIORITY JOURNAL; SODIUM EXCRETION;

AFRICAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RENIN; RISK FACTORS;

EID: 0031015833     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00301-9     Document Type: Article

References (23)

1. Freis ED. Age, Race, sex, and other indices of risk in hypertension. Am J Med. 55:1973;275-280.
2. Kannel WB, Sorlie P. Hypertension in Framingham. Paul O. Epidemiology and Control of Hypertension. 1975;553-592 Stratton International, New York.
3. Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor in essential hypertension: more evidence. Am J Med. 55:1973;295-302.
4. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 286:1972;441-449.
5. Alderman MH, Madhavan S, Ooi WL: Renin-sodium profiling: a predictor of myocardial infarction among hypertensive patients. N Engl J Med 1991;324:1098-104.
6. Alderman MH, Schoenbaum EE. Detection and treatment of hypertension at the work site. N Engl J Med. 293:1975;65-68.
7. Alderman MH, Davis TK. Hypertension control at the work site. J Occup Med. 18:1975;793-796.
8. Sealey JE, Campbell GA, Prebisz JJ. Hormone assays. Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis and Management. 1990;1443-1460 Raven Press, New York.
9. Sealey JE, Atlas SA, Laragh JH. Prorenin and other large molecular weight forms of renin. Endocr Rev. 1:1980;365-391.
10. Sealey JE. Measurement of the hormones of the renin system in hypertensive patients. Clin Biochem. 14:1981;273-281.
11. Rose GA, Blackburn H. Cardiovascular Survey Methods, (WHO monograph series no. 58). 2nd ed. 1982;World Health Organization, Geneva.
12. Cox DR. Regression models and life tables. J R Stat Soc (B). 34:1972;187-220.
13. Hopkins A. BMDP 2L: survival analysis with covariates - Cox models. Dixon WJ. BMDP Statistical Software. 1985;576-594 University of California Press, Berkeley, California.
14. Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med. 119:1993;329-335.
15. Laragh JH, Sealey JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis and management. Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis and Management. 1990;1329-1348 Raven Press, New York.
16. Meade TW, Mellows S, Brozovic M, et al. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 2:1986;533-537.
17. Meade TW, Cooper JA, Pearl WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 329:1993;616-619.
18. Gavras H, Brown JJ, Lever AF. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet. ii:1971;19-22.
19. Kato M, Takeda N, Yang J, Nagano M. The effects of angiotensin converting enzyme inhibitors and the role of the renin-angiotensin-aldosterone system in J-2-N cardiomyopathic hamsters. Jpn Circ J. 56:1992;46-51.
20. Powel JS, Clozel J-P, Muller RKM. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;186-188.
21. Grinstead WC, Young JB. The myocardial renin-angiotenin system: existence, importance, and clinical implications. Am Heart J. 123:1992;1039-1045.
22. Melby JC. Angiotensin-converting enzyme in cardiovascular and adrenal tissues and implications for successful blood pressure management. Schoenberger JA. A Symposium: Hypertension Management Strategies for the 1990s: Focus on Angiotensin-Converting Enzyme (ACE) Inhibition and Reduction of Cardiovascular Risk. Am J Cardiol. 69:1992;2C-7C.
23. Dahlof B, Herlitz H, Aurell M, Hansson L. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotension-aldosterone system. 5:1992;923-926.